key: cord-0991180-cfvhunl3
authors: Kumar, Gagan; Adams, Alex; Hererra, Martin; Rojas, Erine Raybon; Singh, Vartika; Sakhuja, Ankit; Meersman, Mark; Dalton, Drew; Kethireddy, Shravan; Nanchal, Rahul; Guddati, Achuta Kumar
title: Predictors and Outcomes of HAIs in COVID-19 Patients
date: 2020-11-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.11.135
sha: ca3f26627e43e03c72569056ef14ef564fba7aea
doc_id: 991180
cord_uid: cfvhunl3

INTRODUCTION: Healthcare Associated infections (HAI) after a viral illness are important source of morbidity and mortality, this has not been studied well in hospitalized COVID-19 patients. METHODS: We included all COVID-19 positive adult patients (≥18 years) hospitalized between March 1, 2020 to August 5th, 2020. We used CDC definitions of HAI in the acute care setting. Outcomes studied were rates and types of infections and in hospital mortality.. We constructed several multivariable logistic regression models to examine characteristics associated with development of HAI. RESULTS: Of 1565 patients, 140 separate HAIs from 73 different organisms developed in 59 (3.7%) patients. Of these, 23 were gram positive, 39 were gram negative and 11 were fungal. Patient developing HAI did not have higher odds of death (OR 0.85,95%CI 0.40-1.81, p = 0.69). HAIs were associated with use of tocilizumab (OR 5.04, 95%CI 2.4-10.6, p < 0.001), steroids (OR 3.8, 95%CI 1.4-10, p = 0.007), hydroxychloroquine(OR 3.0, 95%CI 1.0-8.8, p = 0.05) and acute kidney injury requiring hemodialysis (OR 3.7, 95%CI 1.1-12.8, p = 0.04). CONCLUSIONS: HAI are common in hospitalized covid-19 patients. Tocilizumab and steroids were associated with increased risk of HAIs.

Secondary infections post viral illnesses occur frequently and may lead to adverse outcomes. In previous influenza epidemics, for example, many deaths were the direct result of secondary bacterial pneumonia (Morens et al., 2008) . Though seemingly common, these infections remain poorly characterized. In a few small studies during the 2009 H1N1 pandemic (Dhanoa et al., 2011) , approximately 19% of cases were reported to have secondary bacterial infection of which Streptococcus pneumoniae was the most common isolate (MacIntyre et al., 2018) .

Reports describing the epidemiology of secondary infections associated with pneumonia are limited and have small sample sizes. Zhou et al reported 50% rate of secondary infection in people who died compared to 1% in survivors . Chen et al reported 4% rates of fungal infection .

Though management strategies for COVID-19 have evolved through the pandemic, use of therapies with immune modulating properties such as IL-6 receptor antagonists and corticosteroids is common. (Geleris et al., 2020 , Jordan et al., 2020 , Morena et al., 2020 , Selvaraj et al., 2020 , Valk et al., 2020 . These medications are used in attempts to quell the hyperactive host immune response that appears to play a key role in clinical deterioration (Wiersinga et al., 2020) . Many patients are also likely to be exposed to antibiotics secondary to ongoing fever which may not necessarily represent superimposed infections.

Further in persons who are critically ill, the use of central venous and urinary catheters is common (O'Grady et al., 2011) . These factors combined likely raise susceptibility to the acquisition of secondary infections in COVID-19.

The goals of this study are to describe the epidemiology of secondary infections after hospitalization for COVID-19 i. Since these are acquired while patients are hospitalized, we used CDC surveillance definition of healthcare associated infection (HAI) to study these infections (Horan et al., 2008) . As an exploratory aim we also attempted to discern risk factors for acquiring such infections.

J o u r n a l P r e -p r o o f

We performed a retrospective analysis of adult covid-19 patients (age ≥18 years) admitted to a large community hospital in a rural setting in Northeast Georgia between March 1, 2020 to June 10th, 2020. COVID-19 patients were identified from our Epic® EMR using ICD10CM and/or CPT codes for COVID-19 and/or positive for SARS CoV-2-PCR. We obtained clinical and demographical details from Epic® Caboodle data warehouse and Cerner APACHE® Outcomes. Systems integration was provided by IPC Global by leveraging their in-Process Data Factory innovation running on an AWS® VPC. We excluded COVID-19 patients who required readmission to the hospital after initial discharge. The study was reviewed and found exempt by Northeast Georgia Health System IRB board.

General management of covid-19 patients: Patients were admitted to ICU if their FiO2 requirement was higher than 50% (> 10LPM of nasal cannula or >50% on high flow oxygen). All patients received therapeutic anticoagulation if they had D-dimer > 2 and SIC score > 3 (Ding et al., 2018) . Initially all admitted patients received hydroxychloroquine till data regarding efficacy was released, thereafter patients did not receive this medication (Shah et al., 2020 , Tang et al., 2020 . We administered tocilizumab if patients met laboratory parameters supportive of cytokine storm which included 3 or more of the following -1. Ferritin >300 ng/mL with doubling within 24 hours, 2. Ferritin >600 ng/mL, 3. LDH >250 U/L, 4. Elevated D dimer (> 2 mcg/mL FEU), 5. High sensitivity CRP greater than 7 mg/L or 6. H score greater than 110. We used convalescent plasma if patients had dyspnea, RR≥30, PF ratio ≤300 or had the treating clinician J o u r n a l P r e -p r o o f adjudicated life-threatening disease. We provided standard CMS guidelines-based management for prevention of VAP, CAUTI and CLABSI.

We reviewed culture data to ascertain the presence of infection. We classified infections as respiratory (tracheal aspirate, bronchoalveolar lavage), blood, urine, and other (body fluids such as pleural cavity, abdominal cavity). We used CDC definitions of healthcare associated infections(HAIs) in the acute care setting (Horan et al., 2008) . We deemed that a HAI was present if cultures were positive and obtained after 3 days of hospital admission. We defined days to positive cultures as time from day of admission to the day the culture was collected..

Since cultures can be negative, we defined 'possible infection' if patient developed fever > 100.4 O f after 3 rd day of admission and there were blood cultures drawn and antibiotics started within 24 hours of this fever. We also included within this definition if WBC count rose to > 15000 after 3 rd day of admission and there were blood cultures drawn and antibiotics started within 24 hours of this elevation in WBC. Possible infection was not included in HAI.

Outcomes: Our primary outcome of interest were rates of HAIs. Secondary outcomes included in hospital mortality.

We performed all statistical analysis using STATA MC 16.0 (Stata-Corp, College Station, Tx). We describe categorical data using frequency count and percentages. We report medians and inter quartile ranges for continuous variables as they were not normally distributed.

We compared demographical and clinical characteristics of persons who had HAIs with those who did not using chi square and Wilcoxon rank tests for categorical and continuous variables, respectively. For all analyses we deemed statistical significance a p-value < 0.05.

We used multivariable logistic regression models to determine factors associated with the development of HAIs in COVID-19. We used single predictor logistic regression to identify significant associations between putative risk factors and development of secondary infections.

Variables found significant at p < 0.10 were candidates for inclusion in our primary model.

Regardless of significance we included variables known to be associated with outcomes in COVID-19 as well as variables previously identified as risk factors for developing secondary infections. Backward elimination method was used to remove other variables from the final model. Final model was bootstrapped using 2,000 bootstrap replicates and case resampling with replacement from the original dataset.

We used multivariable logistic regression analysis to examine association of HAIs with inhospital mortality. Since patients who developed HAIs were sicker and had higher inflammatory markers, we used propensity scores to adjust for these differences. Propensity score was used to identify probability that a patient would receive develop HAIs. This was calculated for every patient. Propensity score was computed using multivariable logistic regression model with HAIs as the dependent variable and incorporating multiple independent variables which included demographic and clinical characteristics along with laboratory markers. The propensity score thus obtained was used as a continuous variable to further adjust the above regression. 

There was male and black race had higher rates of HAIs (Table 1) . Rates of HAIs were higher in co-morbidities such as diabetes mellitus and ESRD (Table 1) . HAIs were observed to be higher in patients receiving treatment for covid-19 such as hydroxychloroquine (27.4% vs 13.6%, p<0.001), convalescent plasma (50.9% vs 14.1%, p<0.001), tocilizumab (66.7% vs 11.6%, J o u r n a l P r e -p r o o f p<0.001) and steroids (78.4% vs 40.2%, p<0.001). Patients who received cefepime and vancomycin on admission developed higher rates of secondary infection (Table 1) .

Sicker patients on admission with higher SOFA score and higher inflammatory markers (such as ferritin, CRP, and d-dimer) developed higher rates of secondary infection (Table 2) .

Patients developing secondary infections were more often on the mechanical ventilation (42.4% vs 10.0%, p<0.001) and had central venous lines (45.8% vs 8.1%, p<0.001).

HAIs were associated with use of tocilizumab (OR 5.04, 95%CI 2.4-10.6, p<0.001), steroids (OR 3.8, 95%CI 1.4-10, p=0.007), hydroxychloroquine(OR 3.0, 95%CI 1.0-8.8, p=0.05) and acute kidney injury requiring hemodialysis (OR 3.7, 95%CI 1.1-12.8, p=0.04). Other medicationsconvalescent plasma and remedesivir were not associated with increased rates of HAIs.

Patients developing secondary infection had significantly higher in hospital mortality when compared to those who did not develop secondary infection ( 40.7% vs 11.8% p<0.001) (Table   4 ). However, on multivariable analysis, secondary infections were not associated with increased risk of death (OR 0.85, 95%CI 0.40-1.80, p=0.67) (Appendix 1).

The length of hospital stay was significantly longer in patients developing secondary infections.

Disposition in patients with secondary infection was significantly higher to skilled nursing facility and long-term acute care (SNF/LTAC) when compared to those who did not have secondary infection (35.3% vs 13.6%, p<0.001).

DISCUSSION COVID-19 pandemic has observed use of immunomodulating medications to help prevent dysregulated immune response also called cytokine storm (Wiersinga et al., 2020) . We report our experience of all COVID-19 patients who were admitted to the hospital till August 5th th ,2020. There were more than 1500 patients, of which 250 patients required intubation from severe COVID-19. We have observed number of patients that develop HAIs to be about 3.7%.

Multiple host and environmental factors determine development of HAI in any hospitalized patient. Secondary infections in post viral infection emanate from increased immune susceptibility, increasing risk for co-infections and HAIs (Hendaus et al., 2015, Smith and McCullers, 2014) . In patients with influenza virus, there is increased susceptibility to bacterial adhesion by bacteria such as Streptococcus and pseudomonas (Pittet et al., 2010) . Antibiotics used for bacterial infections can result in changes in normal flora of the host (Haak and Wiersinga, 2017) . Patients with prolonged hospital course are at risk of nosocomial infections as well.

However, modifiable factors such as -protocols for mitigation of infection, staff education and practices and hospital policies for lines and catheters also play a role. Before COVID-19 pandemic, various CMS measures were in place at our hospital to prevent VAP, CLABSI and J o u r n a l P r e -p r o o f CAUTI. With immense surges of COVID-19, various system in place were under stress and unable to be utilized at their normal capacity. At our center, number of covid-19 patients in the ICU in the peak times ranged from 30 to 45. Our hospital system supported the COVID-19 crisis with additional 50 beds in surge capacity. Both doctors and nursing capacity was increased to cope up with the increase in patient volumes. Due to this extra support, we were still able to perform CMS core measures to a reasonable extent. Our rates of HAI may be difficult to compare to other hospital system due to this reason.

Similar to previous studies on HAIs, use of central venous lines was associated with higher rates of both bacterial and fungal infections (Muskett et al., 2011 , Zhao et al., 2016 . Use of antibiotics was associated with risk of fungal infections. All 11 patients who developed fungal infections received antibiotics on admission. Since most of the COVID-19 patients present with fever, cough and CXR findings of pneumonia, many of these patients receive empiric antibiotics for community acquired pneumonia. However, patients receiving cefepime and vancomycin on admission had higher rates of HAIs.

Tocilizumab has been used very often in COVID-19 due to concerns about cytokine storm from deregulated IL6 pathway being the underlying problem causing the severe disease (Morena et al., 2020) . This drug has been used for MAS-HLH induced cytokine storm in disease like rheumatoid arthritis (Grom et al., 2016) . Its use in ICU has not been studied and is likely not risk free as it blocks IL6R which is an important regulator of immune system. Tocilizumab was J o u r n a l P r e -p r o o f studied in 16,074 rheumatoid arthritis patients and was associated with increased risks bacterial infections -diverticulitis, pneumonia, and bacteremia (Pawar et al., 2019) . Tocilizumab was given to 210 patients with severe COVID-19 at our center, of which 42(20%) developed HAI.

We observed tocilizumab was associated with increased risk of HAIs.. In COVID-19 patients receiving tocilizumab, HAI has been reported to be around 27-32% (Morena et al., 2020 , Rossotti et al., 2020 .

In the initial phase of the pandemic, Hydroxychloroquine, was also used extensively at our center and 220 patients received this medication. Hydroxychloroquine destabilizes lysosomal membranes and promotes the release of lysosomal enzymes inside cells which can inhibit the function of lymphocytes and thus has immunomodulatory and anti -inflammatory effects (Schrezenmeier and Dorner, 2020) . We found its association with HAIs, though the lower limit of confidence interval was one..

Though we have focused on culture positive organisms, there are significant number of patients who may have HAI but were culture negative. Both timing of cultures and use of antibiotics can affect the positivity of culture rates, with up to 50% of infection in ICU being culture negative (Gupta et al., 2016) . To study these patients, we defined any fever/leukocytosis along with getting blood cultures and initiation of empiric antibiotics as possible infection. We observed only 40% culture positive rates when patient qualified as 'possible infection'.

Though we report our experience with over 1500 covid-19 patients, our study has certain limitations. It is a single center study and it would be difficult to extrapolate the results to other centers which may have different support systems, protocols for prevention of infections and usage of COVID-19 medications. Retrospective nature of our study prevents us from drawing any causative risk factors. There may be other underlying factors that we do not know that would affect development of HAI in COVID-19 patients. Lastly, there were missing values with respect to the inflammatory markers. We were therefore unable to use them in our regression models which may have improved our model for this disease.

Despite these limitations, our study provides insight into rates of HAIs in this group of patients 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Epidemiology and clinical characteristics of hospitalized patients with pandemic influenza A (H1N1) 2009 infections: the effects of bacterial coinfection

Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Macrophage activation syndrome in the era of biologic therapy

Culture-Negative Severe Sepsis: Nationwide Trends and Outcomes

The role of the gut microbiota in sepsis

Virus-induced secondary bacterial infection: a concise review

CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

NIH halts clinical trial of hydroxychloroquine

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

Risk factors for invasive fungal disease in critically ill adult patients: a systematic review

Guidelines for the prevention of intravascular catheter-related infections

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae

Roche provides an update on the phase III COVACTA trial of Actemra/R oActemra in hospitalised patients with severe COVID-19 associated pneumonia

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Short-Term Dexamethasone in Sars-CoV-2 Patients

A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19)

Secondary bacterial infections in influenza virus infection pathogenesis

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study